Significance of Nanomedicines and Recent advancement in Vaccine Formulations for Combating SARS-CoV2

Several lines of treatment for COVID-19 are being used worldwide, but to date, the perfect line of therapy is not available. Nanomedicines received success rates in past in treating various viral complications like HCV, HSV1, IAV, HuNoV, IBV, EBOV and HIV1, which could be a game-changer for COVID-19. Various manufacturing units are looking towards nanotechnology and evaluating different nanomedicines and vaccines for treating corona infection. Recently Pfizer achieved great success in developing liposome-based messenger ribonucleic acid vaccine called BNT162b. There are few nanoparticles (NPs) under clinical trials capable of neutralising SARS-CoV-2 in outer surrounding, e.g., GDs-NPs (Gold nanoparticles), Ag-NPs (Silver nanoparticles), CuO-NPs (Copper oxide nanoparticles). The mutation of virus is challenging for treating COVID-19 and intense discovery in field of nanoscience and clinical manifestation of COVID-19 is required. Authors described the significant role of lipid nanoparticles (LNPs) in different vaccine formulations and their utility in nanomedicines for management of COVID-19.